BridgeBio Pharma director sells $13.2m in BBIO stock

In a significant move, a director at BridgeBio Pharma has sold $13.2 million worth of BBIO stock, raising concerns among investors about the company's future. Such large stock sales by insiders can often signal a lack of confidence in the company's performance, leading to speculation and potential volatility in the stock price. This development is particularly noteworthy as it comes at a time when the biotech sector is facing various challenges, making it crucial for stakeholders to closely monitor the situation.